Eddie Eltoukhy

Background

Eddie Eltoukhy is a Partner at Pear VC, where he leads the firm’s life sciences and biotech investment practice ¹. He joined Pear in October 2022 ¹.

Eltoukhy holds a PhD in Biological Engineering from MIT, where his doctoral research under Professors Robert Langer and Daniel Anderson focused on the development of non-viral gene therapies ¹. He subsequently earned an MBA from Stanford University’s Graduate School of Business ¹.

After completing his PhD, Eltoukhy joined an early-stage ocular drug delivery company as a scientist, working on formulation and process scale-up for two clinical drug products that have since received FDA approval ¹. During his MBA at Stanford, he completed internships at Roche/Genentech and at NanoDimension, a venture capital firm, which gave him early exposure to both large pharma and venture investing ¹².

He then joined Senti Biosciences — a Pear VC portfolio company focused on synthetic biology-based cell and gene therapies — as its first business hire, serving as Head of Corporate Development ¹². In that role, he oversaw the company’s growth from seed stage through its preparation for public financing and led the execution of major biopharma partnerships with Spark Therapeutics (Roche) and BlueRock Therapeutics (Bayer) ¹. Senti Biosciences went public via SPAC on Nasdaq (ticker: SNTI) in June 2022 ³.

After Senti Bio’s public debut, Eltoukhy joined Pear VC as Partner in October 2022 to build the firm’s biotech investing practice ¹. He serves as a board observer on Pear biotech portfolio companies, including Xilis, where he leverages his operating and business development experience to guide management on strategy, partnerships, and fundraising ⁴.

Eltoukhy lives in the Bay Area with his wife and three children ⁵. Personal interests include tennis, travel, and playing piano and drums ⁵.

Stated Thesis

(Self-reported: These represent what Eltoukhy says publicly about his investment approach. See Inferred Thesis for analysis of actual behavior.)

Eltoukhy has stated that Pear aims to build “the ideal pre-seed and seed stage investment partnership for Biotech founders,” filling what he identifies as a gap in early-stage life sciences financing ¹. He targets the biotech sector, which he cites as projected to reach $2.4 trillion by 2028, driven by declining DNA synthesis and sequencing costs, AI/ML advancement, favorable regulations, and the expansion of synthetic biology ¹.

His stated investment focus areas at Pear include: (1) novel therapeutic discovery platforms leveraging omics technologies including single-cell sequencing, spatial transcriptomics, and proteomics; (2) next-generation therapeutic modalities such as genomic medicines (gene therapy, RNA therapeutics, gene editing), cell therapies, targeted protein degraders, and antibody-drug conjugates; (3) precision medicine with biomarker-guided drug development; and (4) software platforms for biopharma spanning drug discovery, clinical development, and manufacturing ⁶.

Eltoukhy has articulated a broad view of what determines success in biotech: “To succeed in biotech, the people and the business model matter just as much as the science” ⁵. On the Infinimmune investment, he wrote that Infinimmune “combines a world-class team of technologists with a state-of-the-art platform for the discovery, characterization, and validation of truly human antibodies” and expressed that Pear is “excited about this human-first approach to drug discovery” ⁷.

On the Portal Biotechnologies investment, Eltoukhy stated: “We are very excited to join the Portal team and support their mission to solve one of the field’s major long-standing challenges. Through their platform focused business model, we hope to see broad impact across applications that could ultimately benefit many patients.” ⁸

In February 2023, Eltoukhy promoted Pear’s PearX accelerator program, noting: “We’ve had fantastic biotech & healthcare companies in previous batches” ⁹.

Inferred Thesis

Based on 8 verified investments in the portfolio table below (all made after Eltoukhy joined Pear in October 2022 or represented by Pear’s earlier biotech bets he now shepherds):

Note on sample size: Only 8 investments could be independently verified with sources. Eltoukhy joined Pear in late 2022, so his personal deal count as a VC is limited. The analysis below reflects his verified activity; the sample is too small for reliable percentage breakdowns.

Stage distribution (8 verified investments): - Pre-seed: 2 (Portal Biotechnologies $5M pre-seed 2024; Xilis seed/pre-seed via PearX ~2020) - Seed: 4 (Infinimmune $12M seed 2022; Radar Therapeutics $13.4M seed 2024; Range Bio $5.2M seed 2023; Interface Biosciences $3M seed ~2023) - Series B (follow-on): 1 (Foresight Diagnostics Series B 2023) - Legacy Pear portfolio (pre-Eddie, board observer role): 1 (Valar Labs)

Sector concentration (8 verified investments): All 8 are life sciences / biotech. Within biotech, the breakdown is: - Drug discovery platforms (antibody, RNA, proteomics): 3 (Infinimmune, Radar Therapeutics, Range Bio) - Cell delivery / engineering tools: 1 (Portal Biotechnologies) - Diagnostics / liquid biopsy: 2 (Foresight Diagnostics, Xilis) - AI-guided oncology: 1 (Valar Labs) - Microbiome / inflammation: 1 (Interface Biosciences)

Therapeutic modality focus: Eltoukhy shows particular interest in RNA-based therapeutics and programmable medicines — Radar Therapeutics (RNA sensors), Infinimmune (human antibody discovery), and Range Bio (proteomics) all sit in the “platform-first, modality-agnostic” category. He has stated investment interest in gene therapy and synthetic biology, consistent with his Senti Bio operating background.

Geographic concentration: All verified investments are US-based, with a concentration in California (Bay Area). Xilis is based in Durham, NC; Foresight Diagnostics originated from Stanford/Boulder, CO.

Check size and stage: Pear’s biotech check size is reported as $250K–$10M with a sweet spot of $5M ¹⁰. Confirmed lead-investor status on Portal Biotechnologies ($5M pre-seed) ⁸. Participated as co-investor on Infinimmune ($12M seed led by Playground Global) ⁷, Radar Therapeutics ($13.4M seed led by NfX Bio) ¹¹, Range Bio ($5.2M seed led by ARTIS Ventures) ¹², and Interface Biosciences ($3M seed led by LongeVC) ¹³.

Founder profile patterns: Eltoukhy consistently backs deep-science academic founders transitioning to commercial roles — Xilis (Duke professors), Infinimmune (10x Genomics/Broad Institute alumni), Radar Therapeutics (MIT and Stanford faculty co-founders), Range Bio (proteomics researchers), Interface Biosciences (Stanford PhDs). He has explicitly stated that “the people and the business model matter just as much as the science,” and his board observer role at Xilis focuses specifically on strategy, partnerships, and fundraising coaching — consistent with coaching scientific founders on commercialization.

Co-investor patterns: Pear frequently co-invests with Playground Global (Infinimmune), NfX Bio (Radar), ARTIS Ventures (Range Bio), LongeVC (Interface), Conscience VC and 10x Capital (Portal). Within Pear’s broader portfolio, a16z Bio+Health (BioAge, Valar Labs) and GV/Mubadala (Xilis Series A) appear as follow-on investors.

Notable gap: Eltoukhy’s stated thesis includes software platforms for biopharma, but no verified investments in pure software/AI-for-drug-discovery companies have been documented. His actual portfolio skews toward wet-lab platform biotech and diagnostics.

Portfolio

This table represents approximately 8 verified investments directly tied to Eltoukhy’s role at Pear, plus 2 legacy Pear portfolio companies (Xilis, Valar Labs) where he serves as board observer. Pear VC’s full biotech portfolio predates his arrival; his personal investment count as a VC partner is limited given he joined in October 2022. Portfolio completeness estimate: approximately 60–80% of post-October 2022 biotech investments, based on public press releases and Pear VC’s biotech page.

In Their Own Words

On Pear’s biotech investment philosophy (Pear VC announcement, October 2022): “Eddie is passionate about cutting-edge life sciences technologies, and he loves working to support visionary founders on their missions to transform human health.” ¹ (Note: This is Pear’s characterization of Eltoukhy in the announcement post, not a direct first-person statement by him.)

On what it takes to succeed in biotech (Pear VC team page, accessed March 2026): “To succeed in biotech, the people and the business model matter just as much as the science.” ⁵

On the Infinimmune investment (Pear VC blog, June 2023): “Infinimmune combines a world-class team of technologists with a state-of-the-art platform for the discovery, characterization, and validation of truly human antibodies. We are excited about this human-first approach to drug discovery.” ⁷

On the Portal Biotechnologies investment (BioSpace press release, March 2024): “We are very excited to join the Portal team and support their mission to solve one of the field’s major long-standing challenges. Through their platform focused business model, we hope to see broad impact across applications that could ultimately benefit many patients.” ⁸

On Pear’s PearX accelerator for biotech (Twitter/X, February 2023): “1 week left to join @pearvc’s PearX program! The Pear team works closely with each team for a 14 week sprint that culminates in a highly anticipated Demo Day. We’ve had fantastic biotech & healthcare companies in previous batches. If you’re building in these spaces, please apply!” ⁹

What Founders Say

No independently sourced founder testimonials about Eddie Eltoukhy specifically were found after dedicated search.

The Pear VC biotech page includes a quote from Xiling Shen, CEO of Xilis (a Pear portfolio company where Eltoukhy serves as board observer), about Pear VC broadly: “Pear is always there when we need help or advice, and they are one of our strongest champions, bringing important investors and partners to us.” ⁶ This refers to Pear VC generally and cannot be attributed specifically to Eltoukhy.

The Pear VC biotech vertical page also includes a quote attributed to the “Co-CEOs, Guardant Health” (a Pear legacy portfolio company, pre-dating Eltoukhy’s arrival): “Pear supported us as we grew our technology and our team, treating us like family.” ⁶ This predates Eltoukhy’s role at Pear and refers to the firm broadly.

A Pear VC case study on Xilis notes that Eddie Eltoukhy, in his role as board observer, is “leveraging his previous operating and business development experience to guide Xilis’ management team on company strategy, partnering, and fundraising.” ⁴ This is Pear’s own characterization, not an independent founder testimonial.

Sources